FDA warns on bed-wetting drug

The FDA warned doctors that desmopressin, a drug used to control bed-wetting, can cause some children to have potentially fatal seizures. Because the nasal-spray form of the drug is particularly problematic, the agency revoked its approval for that formulation's use against bed-wetting.

Sold under brand names such as DDAVP, DDVP, and Stimate, among others, desmopressin causes hyponatremia--an abnormally low concentration of sodium in the blood--in certain patients. The agency has received 61 reports of hyponatremic seizures linked to desmopressin, and two deaths.

- see this release
- read the FDA's alert
- here's the FDA's updated information for on desmopressin
- read the WSJ article

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.